DALLAS, TX--(Marketwire - July 14, 2009) -
| Highlighted Links |
|
|
BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has contracted to start conducting independent clinical testing of its patented SHBAN™ Antiviral Hand Sanitizer Solution to prove it kills the H1N1 (Swine) Influenza A virus in compliance with FDA and EPA standards.
In 2007 BioTech conducted an independent study to determine the efficacy of virucidal SHBAN against Avian H5N1 Influenza NIBRG-14 Virus (also known as the Avian Bird Flu). BioTech reported that the SHBAN Solution had clinically proven its anti-viral properties and had topically killed the Avian Influenza virus. Significantly, SHBAN was proven non-toxic with “no cytotoxicity observed on the MDCK cell line after treatment.”
SHBAN is a bio-degradable product superior to most anti-viral and anti-bacterial disinfectants because 1) SHBAN is longer lasting, SHBAN does not evaporate within 15 seconds after application and cease working (like alcohol gels); 2) SHBAN is non-toxic when used as directed on humans and animals; 3) SHBAN is non-staining, non-bleaching; 4) SHBAN is non-flammable and 5) SHBAN has no harmful or toxic odors. Most hand sanitizer products cannot make all of these claims.
BioTech currently sells a 3 oz SHBAN™ Go Anywhere Hand Atomizer Spray Bottle that complies with TSA carry-on travel regulations. SHBAN sales are up significantly in 2009. BioTech is releasing this Fall 1 oz and 16 oz bottles together with SHBAN Hand Wipe Towelettes.
The World Health Organization (WHO) has declared the H1N1 Influenza a worldwide pandemic 6, so it is essential that people buying hand sanitizers know that SHBAN can prove that SHBAN kills the H1N1 Influenza Virus on the hands. SHBAN is protected under US Letters of Patent #5,514,808, #5,574,050, #5,679,711 and #5,585,391 and pending international patents. SHBAN is a trademark of BioTech Medics, Inc. BioTech is seeking and negotiating USA and foreign distributorships at this time.
SHBAN™ in previous in vitro and in vivo testing has been evaluated for its antimicrobial properties against Staph. Aureus, Staph. Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa.
Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the “Act”). The statements above have not been evaluated by the FDA. SHBAN is not intended to diagnose, treat or cure any disease.
Contact:
Tom Wood
Sr. V.P. Sales
Phone 972-849-3782
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
